Pulse Biosciences, Inc (HAM:6L8) Financings
Financings
| Raise | Date |
|---|---|
| At-the-market programme of common stock Tranche closed: US$95.8M raised | Nov 5, 2026 |
| At-the-market programme of common stock Announced: US$75M Use of proceeds: Financing flexibility through key clinical and regulatory milestones | Aug 6, 2026 |
| At-the-market programme of common stock Tranche closed: US$10.7M raised | Aug 6, 2026 |
| Common stock on exercise of warrants Closed: US$1.8M raised | Aug 6, 2026 |
| Warrant exercise of 150% common stock warrants Announced: US$11 a share | Dec 23, 2024 |
| Warrant exercise of warrants exercised for common stock Closed: US$58.4M raised Buyers: Robert W. Duggan (exercised all warrants, corresponding to $58.4 million and 5,306,156 shares) Insiders: Co-Chairman and majority shareholder Robert W. Duggan exercised all of the warrants he acquired in the 2024 rights offering | Dec 19, 2024 |